Proyecto Cenit-Demeter: resultados vitícolas

Desarrollar estrategias y métodos vitícolas y enológicos frente al cambio climático. Aplicación de nuevas tecnologías que mejoren la eficiencia de los procesos resultante

The Validity and Structure of Culture-Level Personality Scores: Data From Ratings of Young Adolescents

We examined properties of culture-level personality traits in ratings of targets (N=5,109) ages 12 to 17 in 24 cultures. Aggregate scores were generalizable across gender, age, and relationship groups and showed convergence with culture-level scores from previous studies of self-reports and observer ratings of adults, but they were unrelated to national character stereotypes. Trait profiles also showed cross-study agreement within most cultures, 8 of which had not previously been studied. Multidimensional scaling showed that Western and non-Western cultures clustered along a dimension related to Extraversion. A culture-level factor analysis replicated earlier findings of a broad Extraversion factor but generally resembled the factor structure found in individuals. Continued analysis of aggregate personality scores is warranted. This article is a US Government work and is in the public domain in the USA.Fil: McCrae, Robert R.. National Institute on Ageing; CanadáFil: Terracciano, Antonio. National Institute on Ageing; CanadáFil: De Fruyt, Filip. University of Ghent; BélgicaFil: De Bolle, Marleen. University of Ghent; BélgicaFil: Gelfand, Michele J.. University of Maryland; Estados UnidosFil: Costa Jr., Paul T.. National Institute on Ageing; CanadáFil: Klinkosz, Waldemar. The John Paul II Catholic University of Lublin; PoloniaFil: Knežević, Goran. Belgrade University; SerbiaFil: Leibovich de Figueroa, Nora. Universidad de Buenos Aires; ArgentinaFil: Löckenhoff, Corinna E.. Cornell University; Estados UnidosFil: Martin, Thomas A.. Susquehanna University; Estados UnidosFil: Marušić, Iris. Institute for Social Research; CroaciaFil: Mastor, Khairul Anwar. Universiti Kebangsaan Malaysia; MalasiaFil: Nakazato, Katsuharu. Iwate Prefectural University; AfganistánFil: Nansubuga, Florence. Makerere University; UgandaFil: Porrata, Jose. No especifíca;Fil: Purić, Danka. Belgrade University; SerbiaFil: Realo, aAnu. University of Tartu; EstoniaFil: Reátegui, Norma. Universidad Peruana Cayetano Heredia; PerúFil: Rolland, Jean Pierre. Universite Paris Ouest Nanterre la Defense; FranciaFil: Schmidt, Vanina Ines. Universidad de Buenos Aires. Facultad de Psicología. Instituto de Investigaciones; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Sekowski, Andrzej. The John Paul II Catholic University of Lublin; PoloniaFil: Shakespeare Finch, Jane. Queensland University of Technology; AustraliaFil: Shimonaka, Yoshiko. Bunkyo Gakuin University; JapónFil: Simonetti, Franco. Pontificia Universidad Católica de Chile; ChileFil: Siuta, Jerzy. Jagiellonian University;Fil: Szmigielska, Barbara. Jagiellonian University;Fil: Vanno, Vitanya. Srinakharinwirot University; TailandiaFil: Wang, Lei. Peking University; ChinaFil: Yik, Michelle. The Hong Kong University of Science and Technology; Hong Kon

Long‐term outcome of immunologic autograft engineering

Abstract Our phase III trial reported that autograft‐absolute lymphocyte count (A‐ALC) improved survival post‐autologous peripheral blood hematopoietic stem cell transplantation (APBHSCT) for a short‐term follow‐up of 2 years. We evaluated retrospectively in our phase III trial patients that the A‐ALC still confers survival benefit with a longer follow‐up. With a median follow‐up of 127.6 months, patients infused with an A‐ALC ≥ 0.5 × 109 cells/kg experienced better overall survival (HR = 0.392, 95% confidence of interval [CI]: 0.224–0.687, p < 0.001) and progression‐free survival (HR = 0.413, 95% CI: 0.253–0.677), p < 0.0004). This study supports that A‐ALC provides long‐term survival benefit post APBHSCT

Outcomes of Patients With Classic Hodgkin Lymphoma Who Relapsed After Autologous Stem Cell Transplant

Immune checkpoint inhibitors (ICIs) and brentuximab vedotin (BV) are novel agents for classic Hodgkin lymphoma, including relapse after autologous stem cell transplant (ASCT). However, their impact on survival post-ASCT relapse, in comparison with conventional therapy, is less known due to the lack of randomized controlled trials. Clinical characteristics and outcomes of 115 patients with relapse (or progression) after ASCT are studied. After a median follow-up of 8.59 years from post-ASCT relapse, the median progression-free survival (PFS) and overall survival (OS) were 0.91 and 5.07 years, respectively. Median lines of therapy after post-ASCT relapse was 2 (range, 1–12). The median PFS was not reached (NR) versus 1.11 versus 0.50 versus 0.85 versus 0.78 years (P = 0.006) and OS was NR versus 7.60 versus 3.08 versus 3.51 versus 3.17 years (P = 0.28) in patients first treated with ICIs versus BV versus investigational agents versus chemotherapy versus radiation therapy (RT). First-line treatment with novel agents (ie, ICIs and BV) was associated with superior outcomes compared with investigational agents and chemotherapy/RT with a median PFS of 1.65 versus 0.50 versus 0.79 years (P = 0.003) and a median OS of 7.60 versus 3.08 versus 3.32 years (P = 0.08). Regardless of lines of therapy, the treatment with ICIs had the most favorable outcome with a median PFS and OS of 3.98 and NR years, respectively. Allogeneic stem cell transplant (allo-SCT) was done in 23 patients (20%), and the median post-allo-SCT PFS and OS were 1.31 and 2.35 years, respectively. In conclusion, survival following post-ASCT relapse improves significantly when patients receive novel agents